CCM
VYNE icon

Corsair Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Corsair Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,000
Closed -$16.8K – 191
2025
Q3 		$16.8K Buy
50,000
+40,000
+400% +$26.2K ﹤0.01% 166
2025
Q2 		$16.5K Buy
+10,000
New +$13K ﹤0.01% 151

Other funds holding VYNE

SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corsair Capital Management's VYNE Position: Q4 2025 in Review

Corsair Capital Management sold out of VYNE Therapeutics (VYNE) in Q4 2025, closing a stake of 50,000 shares — an estimated $16.8K sold.

Corsair Capital Management first reported a position in VYNE in Q2 2025 and held it in 2 quarters. The position peaked at $16.8K in Q3 2025. 44 funds tracked by Wall St. Rank hold VYNE as of Q4 2025.

  • Corsair Capital Management reported no remaining VYNE Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Corsair Capital Management sold 50,000 VYNE Therapeutics shares in Q4 2025, an estimated $16.8K.
  • Corsair Capital Management first reported a position in VYNE Therapeutics in Q2 2025 and held it in 2 quarters.
  • Corsair Capital Management's VYNE Therapeutics position peaked at $16.8K in Q3 2025.
  • 44 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2025.

Based on Corsair Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.